Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.50
Ask: 41.50
Change: 1.00 (2.50%)
Spread: 1.00 (2.469%)
Open: 40.00
High: 41.00
Low: 40.00
Prev. Close: 40.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Feb 2020 15:22

Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell

Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell

Read more
3 Feb 2020 10:17

Avacta signs collaboration deal with Daewoong joint venture

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group announced on Monday that it has signed a collaboration and license agreement with AffyXell Therapeutics - the recently-established joint venture with Daewoong Pharmaceutical - to develop Affimer proteins to be used by AffyXell for the generation of new cell and gene therapies.

Read more
28 Jan 2020 11:57

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Read more
23 Jan 2020 12:44

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Read more
23 Jan 2020 10:28

Avacta doubles revenues thanks to LG Chem milestone payment

(Sharecast News) - Biotherapeutics development outfit Avacta doubled revenues in the 17-month period ended 31 December 2019 as it was boosted by an initial milestone payment from LG Chem.

Read more
21 Jan 2020 12:48

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Read more
8 Jan 2020 15:27

Avacta Group enters joint venture with South Korea's Daewoong

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical, it announced on Wednesday, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies, incorporating its 'Affimer' proteins to enhance the immune-modulatory effects.

Read more
8 Jan 2020 10:40

Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma

Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma

Read more
13 Nov 2019 13:51

Avacta Expands Contract With LG Chem After First Programme Completes

Avacta Expands Contract With LG Chem After First Programme Completes

Read more
13 Nov 2019 11:50

Avacta Group reports solid progress in partnership with LG Chem

(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on the 'Affimer' therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean LG Group, to develop Affimer therapeutics in several disease areas on Wednesday.

Read more
4 Nov 2019 18:15

Avacta Non-Executive Sam Williams Steps Down After General Meeting

Avacta Non-Executive Sam Williams Steps Down After General Meeting

Read more
18 Oct 2019 13:20

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Read more
10 Oct 2019 11:24

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Read more
10 Oct 2019 08:39

Avacta inks collaboration deal with ADC Therapeutics

(Sharecast News) - Biotechnology company Avacta Group has entered a collaboration and option agreement with ADC Therapeutics, which it described as a Switzerland-based clinical-stage oncology-focused biotechnology company pioneering the development of "highly potent and targeted" antibody-drug conjugates for patients suffering from haematological malignancies and solid tumours.

Read more
20 Jun 2019 10:28

Avacta partners with Selexis ahead of first-in-human trials

(Sharecast News) - Avacta Group announced on Thursday that it has partnered with life sciences company Selexis to develop the Chinese hamster ovary (CHO) cell line, which will be used to manufacture Avacta's first 'Affimer' clinical candidate for first-time-in-human clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.